David H Lovett

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10818108/publications.pdf

Version: 2024-02-01

73 papers	3,992 citations	109321 35 h-index	118850 62 g-index
73 all docs	73 docs citations	73 times ranked	4057 citing authors

#	Article	IF	Citations
1	Nonsurgical Periodontal Therapy in CKD: Findings of the Kidney and Periodontal Disease (KAPD) Pilot Randomized Controlled Trial. Kidney Medicine, 2020, 2, 49-58.	2.0	7
2	Myocardial injection of a thermoresponsive hydrogel with reactive oxygen species scavenger properties improves border zone contractility. Journal of Biomedical Materials Research - Part A, 2020, 108, 1736-1746.	4.0	16
3	Enhanced cardiac expression of two isoforms of matrix metalloproteinase-2 in experimental diabetes mellitus. PLoS ONE, 2019, 14, e0221798.	2.5	16
4	Reversal of right ventricular failure by chronic Î±_{1A}-subtype adrenergic agonist therapy. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H224-H232.	3.2	10
5	The two isoforms of matrix metalloproteinase- 2 have distinct renal spatial and temporal distributions in murine models of types 1 and 2 diabetes mellitus. BMC Nephrology, 2018, 19, 248.	1.8	3
6	Short term doxycycline treatment induces sustained improvement in myocardial infarction border zone contractility. PLoS ONE, 2018, 13, e0192720.	2.5	13
7	The expression of two isoforms of matrix metalloproteinase-2 in aged mouse models of diabetes mellitus and chronic kidney disease. Kidney Research and Clinical Practice, 2018, 37, 222-229.	2.2	6
8	An intracellular matrix metalloproteinase-2 isoform induces tubular regulated necrosis: implications for acute kidney injury. American Journal of Physiology - Renal Physiology, 2017, 312, F1166-F1183.	2.7	14
9	Î±_{1A}-Subtype adrenergic agonist therapy for the failing right ventricle. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 313, H1109-H1118.	3.2	19
10	Clear Cell Renal Cell Carcinoma is linked to Epithelial-to-Mesenchymal Transition and to Fibrosis. Physiological Reports, 2017, 5, e13305.	1.7	36
11	Enhanced expression of two discrete isoforms of matrix metalloproteinase-2 in experimental and human diabetic nephropathy. PLoS ONE, 2017, 12, e0171625.	2.5	18
12	Immunosuppression With FTY720 Reverses Cardiac Dysfunction in Hypomorphic ApoE Mice Deficient in SR-BI Expression That Survive Myocardial Infarction Caused by Coronary Atherosclerosis. Journal of Cardiovascular Pharmacology, 2016, 67, 47-56.	1.9	15
13	Novel intracellular Nâ€terminal truncated matrix metalloproteinaseâ€2 isoform in skeletal muscle ischemiaâ€reperfusion injury. Journal of Orthopaedic Research, 2016, 34, 502-509.	2.3	2
14	Two Distinct Isoforms of Matrix Metalloproteinase-2 Are Associated with Human Delayed Kidney Graft Function. PLoS ONE, 2015, 10, e0136276.	2.5	12
15	A N-terminal truncated intracellular isoform of matrix metalloproteinase-2 impairs contractility of mouse myocardium. Frontiers in Physiology, 2014, 5, 363.	2.8	23
16	Myofilament dysfunction contributes to impaired myocardial contraction in the infarct border zone. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H1150-H1158.	3.2	17
17	Matrix metalloproteinase-2 plays a critical role in overload induced skeletal muscle hypertrophy. Muscles, Ligaments and Tendons Journal, 2014, 4, 362-70.	0.3	4
18	Matrix metalloproteinase-2 plays a critical role in overload induced skeletal muscle hypertrophy. Muscles, Ligaments and Tendons Journal, 2014, 4, 446-54.	0.3	12

#	Article	IF	Citations
19	Intraventricular and interventricular cellular heterogeneity of inotropic responses to Î±₁-adrenergic stimulation. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 304, H946-H953.	3.2	29
20	mTOR regulates fatty infiltration through SREBPâ€1 and PPARÎ³ after a combined massive rotator cuff tear and suprascapular nerve injury in rats. Journal of Orthopaedic Research, 2013, 31, 724-730.	2.3	63
21	Muscle extracellular matrix degradation and contractibility following tendon rupture and disuse. Muscles, Ligaments and Tendons Journal, 2013, 3, 35-41.	0.3	12
22	N-Terminal Truncated Intracellular Matrix Metalloproteinase-2 Induces Cardiomyocyte Hypertrophy, Inflammation and Systolic Heart Failure. PLoS ONE, 2013, 8, e68154.	2.5	47
23	A Novel Intracellular Isoform of Matrix Metalloproteinase-2 Induced by Oxidative Stress Activates Innate Immunity. PLoS ONE, 2012, 7, e34177.	2.5	94
24	Evaluation of Akt/mTOR activity in muscle atrophy after rotator cuff tears in a rat model. Journal of Orthopaedic Research, 2012, 30, 1440-1446.	2.3	67
25	Transgenic expression of matrix metalloproteinase-2 induces coronary artery ectasia. International Journal of Experimental Pathology, 2011, 92, 50-56.	1.3	18
26	Telomerase Deficiency in Bone Marrowâ€“Derived Cells Attenuates Angiotensin IIâ€“Induced Abdominal Aortic Aneurysm Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 253-260.	2.4	20
27	Graded activation of the MEK1/MT1-MMP axis determines renal epithelial cell tumor phenotype. Carcinogenesis, 2011, 32, 1806-1814.	2.8	3
28	Role of AP-1 and RE-1 binding sites in matrix metalloproteinase-2 transcriptional regulation in skeletal muscle atrophy. Biochemical and Biophysical Research Communications, 2010, 396, 219-223.	2.1	15
29	YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis. Biochemical and Biophysical Research Communications, 2010, 398, 482-488.	2.1	43
30	Cardiac transgenic matrix metalloproteinase-2 expression induces myxomatous valve degeneration: a potential model of mitral valve prolapse disease. Cardiovascular Pathology, 2009, 18, 253-261.	1.6	29
31	Mechanisms of matrix metalloproteinase-2 (mmp-2) transcriptional repression by progesterone in jar choriocarcinoma cells. Reproductive Biology and Endocrinology, 2009, 7, 41.	3.3	12
32	Associations of interleukinâ€6, Câ€reactive protein and serum amyloid A with mortality in haemodialysis patients. Nephrology, 2008, 13, 593-600.	1.6	29
33	Expression of a G_i-coupled receptor in the heart causes impaired Ca²⁺handling, myofilament injury, and dilated cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H205-H212.	3.2	16
34	Polymeric meshes induce zonal regulation of matrix metalloproteinaseâ€2 gene expression by macrophages and fibroblasts. FASEB Journal, 2007, 21, 1047-1057.	0.5	25
35	Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H1847-H1860.	3.2	161
36	Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction. Biochemical and Biophysical Research Communications, 2007, 358, 189-195.	2.1	61

#	Article	IF	Citations
37	Regulation of MMP-2 Gene Transcription in Dermal Wounds. Journal of Investigative Dermatology, 2007, 127, 1762-1767.	0.7	36
38	Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovascular Research, 2006, 69, 688-696.	3.8	75
39	Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H2216-H2228.	3.2	71
40	Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H1838-H1846.	3.2	91
41	Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB Journal, 2006, 20, 1898-1900.	0.5	212
42	The disintegrin domain of ADAM9: a ligand for multiple Î²1 renal integrins. Biochemical Journal, 2005, 385, 461-468.	3.7	44
43	Interleukin-1 gene cluster polymorphisms predict risk of ESRD. Kidney International, 2005, 68, 278-284.	5.2	34
44	Transcription Factor YB-1 Mediates DNA Polymerase Î± Gene Expression. Journal of Biological Chemistry, 2005, 280, 7702-7711.	3.4	77
45	Intronic regulation of matrix metalloproteinase-2 revealed by in vivo transcriptional analysis in ischemia. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16345-16350.	7.1	58
46	Differential transcriptional activation of matrix metalloproteinase-2 and membrane type-1 matrix metalloproteinase by experimental deep venous thrombosis and thrombin. Journal of Vascular Surgery, 2005, 42, 539-545.	1.1	24
47	Co-operative interactions between NFAT (nuclear factor of activated T cells) c1 and the zinc finger transcription factors Sp1/Sp3 and Egr-1 regulate MT1-MMP (membrane type 1 matrix metalloproteinase) transcription by glomerular mesangial cells. Biochemical Journal, 2004, 380, 735-747.	3.7	51
48	Gelatinase A (MMP-2) Is Necessary and Sufficient for Renal Tubular Cell Epithelial-Mesenchymal Transformation. American Journal of Pathology, 2003, 162, 1937-1949.	3.8	232
49	The prodomain of interleukin 1Î± interacts with elements of the RNA processing apparatus and induces apoptosis in malignant cells. FASEB Journal, 2003, 17, 203-213.	0.5	65
50	Linked Common Polymorphisms in the Gelatinase A Promoter Are Associated with Diminished Transcriptional Response to Estrogen and Genetic Fitness. Journal of Biological Chemistry, 2003, 278, 20490-20499.	3.4	71
51	A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochemical Journal, 2003, 369, 485-496.	3.7	189
52	Transcription Factor Ets-1 Regulates Gelatinase A Gene Expression in Mesangial Cells. Journal of the American Society of Nephrology: JASN, 2002, 13, 1568-1578.	6.1	33
53	Discoidin Domain Receptor 2 Regulates Fibroblast Proliferation and Migration through the Extracellular Matrix in Association with Transcriptional Activation of Matrix Metalloproteinase-2. Journal of Biological Chemistry, 2002, 277, 3606-3613.	3.4	205
54	Combinatorial Interactions of p53, Activating Protein-2, and YB-1 with a Single Enhancer Element Regulate Gelatinase A Expression in Neoplastic Cells. Journal of Biological Chemistry, 2002, 277, 24875-24882.	3.4	56

#	Article	IF	Citations
55	Tumour metastasis suppressor, nm23-Î², inhibits gelatinase A transcription by interference with transactivator Y-box protein-1 (YB-1). Biochemical Journal, 2002, 366, 807-816.	3.7	46
56	The Hematopoietic Transcription Factor PU.1 Represses Gelatinase A Transcription in Glomerular Mesangial Cells. Journal of Biological Chemistry, 2000, 275, 19552-19559.	3.4	16
57	Identification, Cellular Distribution and Potential Function of the Metalloprotease-Disintegrin MDC9 in the Kidney. Journal of the American Society of Nephrology: JASN, 2000, 11, 595-603.	6.1	25
58	YB-1 Regulation of the Human and Rat Gelatinase A Genes via Similar Enhancer Elements. Journal of the American Society of Nephrology: JASN, 1999, 10, 2480-2487.	6.1	44
59	Regulated expression of matrix metalloproteinases and TIMP in nephrogenesis. Developmental Dynamics, 1998, 213, 121-129.	1.8	39
60	A Synergistic Interaction of Transcription Factors AP2 and YB-1 Regulates Gelatinase A Enhancer-dependent Transcription. Journal of Biological Chemistry, 1998, 273, 32957-32965.	3.4	99
61	Glomerular Mesangial Cell-specific Transactivation of Matrix Metalloproteinase 2 Transcription Is Mediated by YB-1. Journal of Biological Chemistry, 1997, 272, 22905-22912.	3.4	136
62	Gelatinase A is a glomerular mesangial cell growth and differentiation factor. Kidney International, 1997, 51, 1397-1400.	5.2	33
63	Pharmacological inhibition of gelatinase B induction and tumor cell invasion. , 1996, 67, 523-531.		31
64	Matrix Metalloproteinase 2 (Gelatinase A) Regulates Glomerular Mesangial Cell Proliferation and Differentiation. Journal of Biological Chemistry, 1996, 271, 15074-15083.	3.4	142
65	Tissue-specific Enhancer-Promoter Interactions Regulate High Level Constitutive Expression of Matrix Metalloproteinase 2 by Glomerular Mesangial Cells. Journal of Biological Chemistry, 1995, 270, 18786-18796.	3.4	88
66	Asymmetric origins of the mature glomerular basement membrane. Journal of Cellular Physiology, 1993, 157, 169-177.	4.1	26
67	Proteinases and glomerular matrix turnover. Kidney International, 1992, 41, 671-678.	5.2	148
68	Interleukin 1: The patterns of translation and intracellular distribution support alternative secretory mechanisms. Journal of Cellular Physiology, 1992, 152, 223-231.	4.1	82
69	Human mesangial cells secrete a GBM-degrading neutral proteinase and a specific inhibitor. Kidney International, 1989, 36, 790-801.	5.2	79
70	Interleukin 1 and the glomerular mesangium. III. IL-1-dependent stimulation of mesangial cell protein kinase activity. Kidney International, 1988, 34, 26-35.	5.2	42
71	Insulin and Insulin-Like Growth Factor I Binding to Cultured Rat Glomerular Mesangial Cells*. Endocrinology, 1988, 123, 2432-2439.	2.8	66
72	Cell culture approaches to the analysis of glomerular inflammation. Kidney International, 1986, 30, 246-254.	5.2	98

#	Article	IF	Citations
73	Neutral proteinase activity produced in vitro by cells of the glomerular mesangium. Kidney International, 1983, 23, 342-349.	5.2	141